Anderson Financial Strategies LLC Invests $197,000 in IDEXX Laboratories, Inc. $IDXX

Key Points

• Anderson Financial Strategies LLC purchased a new stake of 468 shares in IDEXX Laboratories, valued at approximately $197,000, as reported in their recent SEC filing.
• Several equity research analysts have set varied target prices for IDEXX Laboratories, with BTIG Research increasing its target from $545 to $785 and giving it a "buy" rating.
• IDEXX Laboratories reported earnings of $3.63 per share for the quarter, surpassing the consensus estimate by $0.35, and anticipates a fiscal year 2025 EPS of between $12.400 and $12.760.

Anderson Financial Strategies LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 468 shares of the company's stock, valued at approximately $197,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Sage Mountain Advisors LLC grew its stake in IDEXX Laboratories by 3.8% during the first quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock worth $267,000 after buying an additional 23 shares during the period. Great Lakes Advisors LLC boosted its position in IDEXX Laboratories by 0.9% during the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company's stock worth $1,078,000 after purchasing an additional 23 shares during the period. PDS Planning Inc increased its holdings in IDEXX Laboratories by 3.9% in the 1st quarter. PDS Planning Inc now owns 641 shares of the company's stock valued at $269,000 after purchasing an additional 24 shares in the last quarter. King Luther Capital Management Corp increased its holdings in IDEXX Laboratories by 0.5% in the 1st quarter. King Luther Capital Management Corp now owns 4,896 shares of the company's stock valued at $2,056,000 after purchasing an additional 24 shares in the last quarter. Finally, Bigelow Investment Advisors LLC raised its position in IDEXX Laboratories by 1.9% in the first quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company's stock valued at $596,000 after purchasing an additional 27 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IDXX shares. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a research report on Monday, August 4th. BTIG Research upped their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Wall Street Zen upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. Finally, Leerink Partners raised their price target on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $649.44.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the transaction, the executive vice president owned 11,287 shares of the company's stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael Lane sold 8,411 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president owned 7,132 shares of the company's stock, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their position. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock valued at $34,293,468 over the last 90 days. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Trading Down 2.7%

IDXX opened at $637.95 on Thursday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The stock has a market capitalization of $51.04 billion, a PE ratio of 53.12, a P/E/G ratio of 4.25 and a beta of 1.56. The firm's fifty day moving average price is $599.72 and its 200 day moving average price is $510.79.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company's revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.